var data={"title":"Amphetamine sulfate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amphetamine sulfate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7472?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amphetamine-sulfate-drug-information\" class=\"drug drug_general\">see &quot;Amphetamine sulfate: Drug information&quot;</a> and <a href=\"topic.htm?path=amphetamine-sulfate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amphetamine sulfate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27122182\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Abuse potential (Adzenys ER, Adzenys XR-ODT, Dyanavel XR, Evekeo):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines have a high potential for abuse and dependence. Administration of amphetamines for prolonged periods of time may lead to drug dependence and must be avoided. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy. Particular attention should be paid to the possibility of subjects obtaining amphetamines for non-therapeutic use or distribution to others, and the drugs should be prescribed or dispensed sparingly.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiovascular events (Evekeo):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Misuse of amphetamine may cause sudden death and serious cardiovascular adverse events.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27121718\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Adzenys ER;</li>\n      <li>Adzenys XR-ODT;</li>\n      <li>Dyanavel XR;</li>\n      <li>Evekeo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F986726\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Stimulant</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F986737\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=amphetamine-sulfate-drug-information\" class=\"drug drug_general\">see &quot;Amphetamine sulfate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Individualize and titrate to lowest effect dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Attention-deficit/hyperactivity disorder:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release tablet: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 3 to 5 years: Oral: Initial: 2.5 mg once daily; increase daily dose in 2.5 mg increments at weekly intervals until optimal response is obtained; first dose should be given at awakening; additional daily doses (1 to 2 doses) may be necessary and should be separated by 4 to 6 hour intervals. Maximum dose not specified; in children &ge; 6 years, daily doses &gt;40 mg/day are rarely necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;6 years and Adolescents: Oral: Initial: 5 mg once or twice daily; increase daily dose in 5 mg increments at weekly intervals until optimal response is obtained; first doses should be given at awakening; additional daily doses (1 to 2 doses) may be necessary and should be separated by 4 to 6 hour intervals. Only in rare cases will it be necessary to exceed 40 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release suspension: Children &ge;6 years and Adolescents: Oral: Initial: 2.5 or 5 mg once daily in the morning; may increase in 2.5 to 10 mg/day increments every 4 to 7 days until optimal response is obtained; maximum daily dose: 20 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Do not substitute extended release formulation for other amphetamine products on a mg-per-mg basis since base composition and pharmacokinetic profiles are not similar. If switching from other amphetamine products, discontinue that treatment, and titrate as per the recommended dosing schedule. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Exogenous obesity:</b> Immediate release tablet: Children &ge;12 years and Adolescents: Oral: Initial: 5 to 10 mg once daily; titrate in 5 to 10 mg increments (at a minimum of weekly intervals); maximum daily dose: 30 mg/<b>day</b> in divided doses  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Narcolepsy:</b>  Immediate release tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to 12 years: Oral: Initial: 5 mg once daily; increase daily dose in 5 mg increments at weekly intervals until optimal response is obtained; first doses should be given at awakening; additional daily doses (5 or 10 mg) may be necessary and should be separated by 4 to 6 hour intervals; usual daily dosage range: 5 to 60 mg daily in divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Oral: Initial: 10 mg once daily; increase daily dose in 10 mg increments at weekly intervals until optimal response is obtained; first doses should be given at awakening; additional daily doses (5 or 10 mg) may be necessary and should be separated by 4 to 6 hour intervals; usual daily dosage range: 5 to 60 mg daily in divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Administer at the lowest effective dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Exogenous obesity:</b> Oral: Immediate release tablet: Up to 30 mg daily in divided doses (5 to 10 mg per dose)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Narcolepsy:</b> Oral: Immediate release tablet: Initial: 10 mg once daily; increase daily dose in 10 mg increments at weekly intervals until optimal response is obtained; usual dosage range: 5 to 60 mg daily in divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F238394\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Extended Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adzenys ER: 1.25 mg/mL (450 mL) [contains fd&amp;c yellow #6 (sunset yellow), methylparaben, polyethylene glycol, propylene glycol, propylparaben; orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Extended Release, Oral, as base: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dyanavel XR: 2.5 mg/mL (464 mL) [contains methylparaben, polysorbate 80, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Evekeo: 5 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Evekeo: 10 mg [scored; contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release Disintegrating, Oral, as base: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adzenys XR-ODT: 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27121717\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27147457\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49626319\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adzenys ER: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204325s000lbl.pdf#page=26&amp;token=m/dLC+5T7rXrL8MbA/LVQjQbNamAxLllVRPwlJpvRCcanbJxGCQryszVu20IpIGIzhf5EEH6i6VSfgr5EmvFgVHsQoBFWRTppQ9B6tbjNPdjUrDEZc6rIhWWbX7aTQE0&amp;TOPIC_ID=103885\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204325s000lbl.pdf#page=26</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dyanavel XR: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208147s003lbl.pdf#page=15&amp;token=sBIY10Diit247RK6PVnD07L/FcxDTd6VNGMQpYhFKbM5TEZvm4SFWCHxK+aRi0sJZX02YqTH2MW7p9lrkewtDinpq9/ksGjhIqeKHA/uuFFPlPjuNGcgFTjE2tQKQ1uh&amp;TOPIC_ID=103885\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208147s003lbl.pdf#page=15</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mydayis: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022063s000lbl.pdf#page=22&amp;token=rd38vxqSlf/zuf733AYqNbmhqEHWeg/PE127aQeSz4gNCCBhqRmiFKk/DzeOyQ90kkTPvOn+eO15kGPg1Vhh2GszQhJc2CTfbVEQMHgPWtwJfU8NsskQmJvCeyEt6blc&amp;TOPIC_ID=103885\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022063s000lbl.pdf#page=22</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29741312\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with or without food; for short-term adjunct treatment of exogenous obesity, administer 30 to 60 minutes before meals. For ADHD and narcolepsy, administer the first dose on awakening; administer additional doses at intervals of 4 to 6 hours. Avoid late evening dosing. Shake suspension well before administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27139062\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted from 15&ordm;C to 30&ordm;C (59&ordm;F to 86&ordm;F). Store orally disintegrating tablet blister packages in travel case provided.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F986727\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release tablet (Evekeo): Treatment of ADHD (FDA approved in ages &ge;3 years through adolescence); narcolepsy (FDA approved in ages &ge;6 years and adults); exogenous obesity (FDA approved in ages &ge;12 years and adults) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release suspension (Dyanavel XR): Treatment of attention-deficit/hyperactivity disorder (ADHD) (FDA approved in ages 6 to 17 years)  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27261244\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As reported in children and adults unless otherwise noted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Increased blood pressure, palpitations, Raynaud's phenomenon, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, dysphoria, euphoria, exacerbation of Gilles de la Tourette's syndrome, headache, insomnia, overstimulation, psychosis, restlessness, tics (including exacerbation), vocal tics (exacerbation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Change in libido, growth suppression (children), weight loss (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, constipation, diarrhea, dysgeusia, gastrointestinal disease, upper abdominal pain, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Erectile dysfunction (frequent or prolonged erections), impotence</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Dyskinesia, rhabdomyolysis, tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Allergic rhinitis, epistaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Mania, peripheral vascular disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F238399\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Hypersensitivity or idiosyncrasy to amphetamine, other sympathomimetic amines, or any component of the formulation; advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; agitated states; history of drug abuse; use during or within 14 days following MAO inhibitor.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Hypersensitivity to amphetamine or any component of the formulation, anaphylactic reactions and angioedema have been reported; use during or within 14 days following MAO inhibitor (including linezolid or intravenous methylene blue).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for amphetamines is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F238383\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: <b>[US Boxed Warning; Immediate release]: Misuse may cause serious cardiovascular events including sudden death.</b> Adverse effects have been reported at usual doses in patients with preexisting structural cardiac abnormalities or other serious heart problems (sudden death in children and adolescents; sudden death, stroke, and MI in adults). These products should be avoided in the patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that could increase the risk of sudden death that these conditions alone carry. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy. Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during treatment should undergo a prompt cardiac evaluation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May impair the ability to engage in potentially hazardous activities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Angioedema and anaphylactic reactions have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension/tachycardia: May occur; monitor blood pressure and heart rate in all patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral vasculopathy: Stimulants are associated with peripheral vasculopathy, including Raynaud phenomenon; signs/symptoms are usually mild and intermittent, and generally improve with dose reduction or discontinuation. Digital ulceration and/or soft tissue breakdown have been observed rarely; monitor for digital changes during therapy and seek further evaluation (eg, rheumatology) if necessary (Syed 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) may occur when amphetamine is used in combination with other serotonergic agents (eg, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, St. John's wort, tryptophan), agents that impair metabolism of serotonin (eg, monoamine oxidase inhibitors) or CYP2D6 inhibitors that impair metabolism of amphetamine. Concomitant use with monoamine oxidase inhibitors is contraindicated. If concomitant use of amphetamine with serotonergic drugs or CYP2D6 inhibitors is indicated, initiate amphetamine at a low dose and monitor patient closely for signs and symptoms of SS. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Visual disturbance: Difficulty in accommodation and blurred vision has been reported with the use of stimulants.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse potential: <b>[US Boxed Warning]: Potential for drug abuse and dependency exists; prolonged use may lead to drug dependency and must be avoided. Assess the risk for abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy. Consider the possibility of patients obtaining amphetamines for non-therapeutic use or distribution to others; prescribe sparingly.</b> Use of immediate-release formulation is contraindicated in patients with history of drug abuse. Write prescriptions for the smallest quantity consistent with good patient care to minimize possibility of overdose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with hypertension and other cardiovascular conditions that might be exacerbated by increases in blood pressure or heart rate (eg, pre-existing hypertension, heart failure, recent MI, ventricular arrhythmia). Use of immediate-release formulation is contraindicated in patients with advanced arteriosclerosis, moderate to severe hypertension, or symptomatic cardiovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disorders: Use with caution in patients with preexisting psychosis or bipolar disorder; may exacerbate symptoms of behavior and thought disorder or induce mixed/manic episode, respectively. Screen patients with comorbid depressive symptoms prior to initiating treatment to determine if they are at risk for bipolar disorder, including a family history of suicide, bipolar disorder, and depression. May be associated with aggressive behavior or hostility (causal relationship not established); monitor for development or worsening of these behaviors. New-onset psychosis or mania may also occur with stimulant use; consider discontinuing therapy if hallucinations, delusional thinking, or mania occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Limited information exists regarding amphetamine use in seizure disorder (Cortese 2013). Use with caution in patients with a history of seizure disorder; may lower seizure threshold leading to new onset or breakthrough seizure activity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tourette syndrome/tics: Use with caution in patients with Tourette syndrome or other tic disorders. Stimulants may exacerbate tics (motor and phonic) and Tourette syndrome; however, evidence demonstrating increased tics is limited. Evaluate for tics and Tourette syndrome prior to therapy initiation (AACAP [Murphy 2013]; Pliszka 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Appetite suppression may occur; monitor weight during therapy. Use of stimulants has been associated with weight loss and slowing of growth rate; monitor growth rate and weight during treatment. Treatment interruption may be necessary in patients who are not increasing in height or gaining weight as expected.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Dosage form specific issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intestinal necrosis: Adzenys ER: Cases of intestinal necrosis, including some deaths, have been reported with the concomitant use of sodium polystyrene sulfonate and sorbitol, two of the inactive ingredients in Adzenys ER. In these cases, patients were administered sodium polystyrene sulfonate at doses greater than 200 times the amount present in Adzenys ER, however no absolute safe levels for the interaction of sodium polystyrene sulfonate and sorbitol have been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Abrupt discontinuation following high doses or for prolonged periods may result in symptoms for withdrawal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29741310\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Serious cardiovascular events, including sudden death, may occur in patients with preexisting structural cardiac abnormalities or other serious heart problems. Sudden death has been reported in children and adolescents; sudden death, stroke, and MI have been reported in adults. Avoid the use of amphetamines in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that could place patients at an increased risk to the sympathomimetic effects of amphetamines. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy. The American Heart Association recommends that all children diagnosed with ADHD who may be candidates for medication, such as amphetamine, should have a thorough cardiovascular assessment prior to initiation of therapy. This assessment should include a combination of medical history, family history, and physical examination focusing on cardiovascular disease risk factors. An ECG is not mandatory but should be considered. If a child displays symptoms of cardiovascular disease, including chest pain, dyspnea, or fainting, parents should seek immediate medical care for the child. In a recent retrospective study on the possible association between stimulant medication use and sudden death in children, 564 previously healthy children who died suddenly in motor vehicle accidents were compared to a group of 564 previously healthy children who died suddenly. Two of the 564 (0.4%) children in motor vehicle accidents were taking stimulant medications compared to 10 of 564 (1.8%) children who died suddenly. While the authors of this study conclude there may be an association between stimulant use and sudden death in children, there were a number of limitations to the study and the FDA cannot conclude this information impacts the overall risk:benefit profile of these medications (Gould 2009). In a large retrospective cohort study involving 1,200,438 children and young adults (aged 2 to 24 years), none of the currently available stimulant medications or atomoxetine were shown to increase the risk of serious cardiovascular events (ie, acute MI, sudden cardiac death, or stroke) in current (adjusted hazard ratio: 0.75; 95% CI: 0.31 to 1.85) or former (adjusted hazard ratio: 1.03; 95% CI: 0.57 to 1.89) users compared to nonusers. It should be noted that due to the upper limit of the 95% CI, the study could not rule out a doubling of the risk, albeit low (Cooper 2011). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Stimulant medications may increase blood pressure (average increase: 2 to 4 mm Hg) and heart rate (average increase: 3 to 6 bpm); some patients may experience greater increases.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Long-term effects in pediatric patients have not been determined. Use of stimulants in children has been associated with growth suppression; monitor growth; treatment interruption may be needed. Appetite suppression may occur; monitor weight during therapy, particularly in children. Evaluation of the effect of stimulants on growth in ADHD diagnosed children &lt;12 years receiving treatment for at least 3 years with stimulants has shown decreased height and weight changes over time compared to age matched control; height: 4.7 to 5.5 cm/year compared to 6.3 cm/year and 2.1 to 3.3 kg/year compared to 4.4 kg/year (Poulton 2016). In pediatric patients 8 to 17 years actively treated with stimulants, significant reductions in total femoral, femoral neck, and lumbar bone mineral density (BMD) were observed compared to matched unmedicated cohorts; also reported were significantly more subjects in the stimulant-treated group with BMD measurements in the osteopenic range compared to matched cohorts (38.3% to 21.6%) (Howard 2015). A longitudinal cohort-controlled trial reported no different in peak height velocity and final adult height in subjects with ADHD and/or treated with stimulants (Harstad 2014). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298743\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F238387\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=103885&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acebrophylline: May enhance the stimulatory effect of CNS Stimulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alkalinizing Agents: May decrease the excretion of Amphetamines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ammonium Chloride: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the excretion of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihistamines: Amphetamines may diminish the sedative effect of Antihistamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihypertensive Agents: Amphetamines may diminish the antihypertensive effect of Antihypertensive Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: May diminish the stimulatory effect of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ascorbic Acid: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May decrease the excretion of Amphetamines.<b> Exceptions: </b>Brinzolamide; Dorzolamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethosuximide: Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Acidifying Agents: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Amphetamines may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May diminish the stimulatory effect of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methenamine: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Amphetamines. While linezolid and tedizolid may interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to monographs specific to those agents for details.<b> Exceptions: </b>Linezolid; Tedizolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May decrease the serum concentration of Amphetamines. More specifically, the ascorbic acid (vitamin C) in many multivitamins may decrease amphetamine concentrations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Amphetamines. Specifically, vitamin C may impair absorption of amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: Amphetamines may enhance the analgesic effect of Opioid Analgesics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: Amphetamines may decrease the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Amphetamines may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May increase the absorption of Amphetamine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urinary Acidifying Agents: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29111983\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Amphetamine serum levels may be reduced if taken with acidic food, juices, or vitamin C. Management: Monitor response when taken concurrently.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F238388\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27122183\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse effects have been observed in animal reproduction studies. Information related to use of amphetamine in pregnancy is limited (Maurovich-Horvat 2012). The majority of human data are based on illicit amphetamine/methamphetamine exposure and not from therapeutic maternal use (Golub 2005). Use of amphetamines during pregnancy may lead to an increased risk of premature birth and low birth weight; newborns may experience symptoms of withdrawal. Behavioral problems may also occur later in childhood (LaGasse 2012). Newborns should be monitored for agitation, irritability, excessive drowsiness, or feeding difficulties</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F986739\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CNS activity, blood pressure, pulse; height, weight, growth parameters; appetite; signs/symptoms of misuse, abuse, addiction, tolerance or dependence; behavioral changes; signs of peripheral vasculopathy (eg, digital changes)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">ADHD: Evaluate patients for cardiac disease prior to initiation of therapy with thorough medical history, family history, and physical exam; consider ECG; perform ECG and echocardiogram if findings suggest cardiac disease; promptly conduct cardiac evaluation in patients who develop chest pain, unexplained syncope, or any other symptom of cardiac disease during treatment. Monitor CNS activity, blood pressure, heart rate, sleep, appetite, abnormal movements, height, weight, BMI, growth in children. Patients should be reevaluated at appropriate intervals to assess continued need of the medication. Observe for signs/symptoms of aggression or hostility, or depression. Monitor for visual disturbances.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F238381\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Amphetamines are noncatecholamine sympathomimetic amines that promote release of catecholamines (primarily dopamine and norepinephrine) from their storage sites in the presynaptic nerve terminals. A less significant mechanism may include their ability to block the reuptake of catecholamines by competitive inhibition. The anorexigenic effect is probably secondary to the CNS-stimulating effect; the site of action is probably the hypothalamic feeding center. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F238398\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Alkaline urine pH will result in reduced renal elimination of amphetamine and acidic urine pH will result in increased renal elimination. Decreased renal elimination in the context of alkaline urine pH may be more pronounced when renal elimination is already decreased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of action: Adzenys XR-ODT: 10 to 12 hours; Evekeo: 4 to 6 hours (Jain 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Evekeo: Rapid (de la Torre 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Oral: Evekeo: V<sub>d</sub>: 3 to 4 L/kg (de la Torre 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Oral: Evekeo: 16% (de la Torre 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via oxidation, deamination, and CYP2D6</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dyanavel XR: 106% of d-amphetamine and 111% for l-amphetamine (relative to equivalent dose of immediate-release mixed amphetamine salts)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Evekeo: Good (de la Torre 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adzenys ER:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to 12 years: d-amphetamine 12.7 hours (mean) and l-amphetamine 15.3 hours (mean)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: d-amphetamine 11.4 hours (mean) and l-amphetamine 14.1 hours (mean)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adzenys XR-ODT:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to 12 years: d-amphetamine 9 to 10 hours (mean) and l-amphetamine 10 to 11 hours (mean)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: d-amphetamine 11 hours (mean) and l-amphetamine 14 hours (mean)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dyanavel XR:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: d-amphetamine 10.43 &plusmn; 2.01 hours and l-amphetamine 12.14 &plusmn; 3.15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: d-amphetamine 12.36 &plusmn; 2.95 hours and l-amphetamine 15.12 &plusmn; 4.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Evekeo: 12 hours (de la Torre 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adzenys ER: d-amphetamine and l-amphetamine: 5 hours (median) with or without food</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adzenys XR-ODT: Median time d-amphetamine 5 hours (7 hours with food) and l-amphetamine ~5.25 hours (7.75 hours with food)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dyanavel XR:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: Median time d-amphetamine 3.9 hours and l-amphetamine 4.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: 4 (2 to 7) hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Evekeo: Within 4 hours (de la Torre 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (30% to 40% unchanged; ~50% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29741313\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Evekeo contains d-amphetamine and l-amphetamine in a 1:1 ratio.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dyanavel XR contains d-amphetamine and l-amphetamine in a 3.2:1 ratio.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of ADHD should include &quot;drug holidays&quot; or periodic discontinuation of medication in order to assess the patient's requirements, decrease tolerance, and limit suppression of linear growth and weight. Medications used to treat ADHD should be part of a total treatment program that may include other components, such as psychological, educational, and social measures.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27265711\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension Extended Release</b> (Adzenys ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.25 mg/mL (450 mL): $768.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension Extended Release</b> (Dyanavel XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg/mL (464 mL): $1,277.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Extended Release Dispersible</b> (Adzenys XR-ODT Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.1 mg (30): $383.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6.3 mg (30): $383.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9.4 mg (30): $383.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (30): $383.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15.7 mg (30): $383.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">18.8 mg (30): $383.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Evekeo Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $762.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $762.90</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adderall XR (amphetamine) [prescribing information]. Wayne, PA: Shire US Inc; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Association of Pediatrics, Section on Breastfeeding. Breastfeeding and the use of human milk. <i>Pediatrics</i>. 2012;129(3):e827-e841<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphetamine-sulfate-pediatric-drug-information/abstract-text/22371471/pubmed\" target=\"_blank\" id=\"22371471\">22371471</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists Committee on Health Care for Underserved Women. Committee Opinion No. 479: Methamphetamine abuse in women of reproductive age. <i>Obstet Gynecol</i>. 2011;117(3):751-755.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphetamine-sulfate-pediatric-drug-information/abstract-text/21343793 /pubmed\" target=\"_blank\" id=\"21343793 \">21343793 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphetamine-sulfate-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper WO, Habel LA, Sox CM, et al, &quot;ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults,&quot; <i>N Engl J Med</i>, 2011, 365(20):1896-904.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphetamine-sulfate-pediatric-drug-information/abstract-text/22043968/pubmed\" target=\"_blank\" id=\"22043968\">22043968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortese S, Holtmann M, Banaschewski T, et al; European ADHD Guidelines Group. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medication in children and adolescents. <i>J Child Psychol Psychiatry</i>. 2013;54(3): 227-246.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphetamine-sulfate-pediatric-drug-information/abstract-text/23294014/pubmed\" target=\"_blank\" id=\"23294014\">23294014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de la Torre R, Farr&eacute; M, Navarro M, Pacifici R, Zuccaro P, Pichini S. Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices. <i>Clin Pharmacokinet</i>. 2004;43(3):157-185.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphetamine-sulfate-pediatric-drug-information/abstract-text/14871155 /pubmed\" target=\"_blank\" id=\"14871155 \">14871155 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dyanavel XR (amphetamine) [prescribing information]. Monmouth Junction, NJ: Tris Pharma; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Evekeo (amphetamine) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, Inc; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Golub M, Costa L, Crofton K, et al, &quot;NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Amphetamine and Methamphetamine,&quot; <i>Birth Defects Res B Dev Reprod Toxicol</i>, 2005, 74(6):471-584.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphetamine-sulfate-pediatric-drug-information/abstract-text/16167346/pubmed\" target=\"_blank\" id=\"16167346\">16167346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould MS, Walsh BT, Munfakh JL, et al, &quot;Sudden Death and Use of Stimulant Medications in Youths,&quot; <i>Am J Psychiatry</i>, 2009, 166(9):992-1001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphetamine-sulfate-pediatric-drug-information/abstract-text/19528194/pubmed\" target=\"_blank\" id=\"19528194\">19528194</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harstad EB, Weaver AL, Katusic SK, et al. ADHD, stimulant treatment, and growth: a longitudinal study. <i>Pediatrics</i>. 2014;134(4):e935-944.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphetamine-sulfate-pediatric-drug-information/abstract-text/25180281 /pubmed\" target=\"_blank\" id=\"25180281 \">25180281 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howard JT, Walick KS, Rivera JC. Preliminary evidence of an association between ADHD medications and diminished bone health in children and adolescents.<i> J Pediatr Orthop</i>. 2015 Sep 20. [Epub ahead of print]<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphetamine-sulfate-pediatric-drug-information/abstract-text/26398435 /pubmed\" target=\"_blank\" id=\"26398435 \">26398435 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphetamine-sulfate-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LaGasse LL, Derauf C, Smith LM, et al. Prenatal methamphetamine exposure and childhood behavior problems at 3 and 5 years of age. <i>Pediatrics</i>. 2012;129(4):681-688.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphetamine-sulfate-pediatric-drug-information/abstract-text/22430455/pubmed\" target=\"_blank\" id=\"22430455\">22430455</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphetamine-sulfate-pediatric-drug-information/abstract-text/26344706/pubmed\" target=\"_blank\" id=\"26344706\">26344706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maurovich-Horvat E, Kemlink D, H&ouml;gl B, et al. Narcolepsy and pregnancy: a retrospective European evaluation of 249 pregnancies. <i>J Sleep Res</i>. 2013;22(5):496-512.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphetamine-sulfate-pediatric-drug-information/abstract-text/23560595/pubmed\" target=\"_blank\" id=\"23560595\">23560595</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &Ouml;hman I, Wikner BN, Beck O, Sarman I. Narcolepsy treated with racemic amphetamine during pregnancy and breastfeeding. <i>J Hum Lact</i>. 2015;31(3):374-376.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphetamine-sulfate-pediatric-drug-information/abstract-text/25948577/pubmed\" target=\"_blank\" id=\"25948577\">25948577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pliszka S and AACAP Work Group on Quality Issues, &quot;Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2007, 46(7):894-921.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphetamine-sulfate-pediatric-drug-information/abstract-text/17581453/pubmed\" target=\"_blank\" id=\"17581453\">17581453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poulton AS, Bui Q, Melzer E, Evans R. Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study. <i>Int Clin Psychopharmacol</i>. 2016;31(2):93-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphetamine-sulfate-pediatric-drug-information/abstract-text/26544899 /pubmed\" target=\"_blank\" id=\"26544899 \">26544899 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steiner E, Vill&eacute;n T, Hallberg M, Rane A. Amphetamine secretion in breast milk. <i>Eur J Clin Pharmacol</i>. 1984;27(1):123-124.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphetamine-sulfate-pediatric-drug-information/abstract-text/6489423/pubmed\" target=\"_blank\" id=\"6489423\">6489423</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Syed RH, Moore TL. Methylphenidate and dextroamphetamine-induced peripheral vasculopathy. <i>J Clin Rheumatol</i>. 2008;14(1):30-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphetamine-sulfate-pediatric-drug-information/abstract-text/18431096 /pubmed\" target=\"_blank\" id=\"18431096 \">18431096 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 103885 Version 51.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F27122182\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F27121718\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F986726\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F986737\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F238394\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F27121717\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F27147457\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F49626319\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F29741312\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F27139062\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F986727\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F27261244\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F238399\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F238383\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F29741310\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298743\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F238387\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F29111983\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F238388\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F27122183\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F986739\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F238381\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F238398\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F29741313\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F27265711\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/103885|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amphetamine-sulfate-drug-information\" class=\"drug drug_general\">Amphetamine sulfate: Drug information</a></li><li><a href=\"topic.htm?path=amphetamine-sulfate-patient-drug-information\" class=\"drug drug_patient\">Amphetamine sulfate: Patient drug information</a></li></ul></div></div>","javascript":null}